The PRESTIGE-AF project (2017-2024) brought together scientists and clinicians from across Europe to determine the best way to reduce the risk of further stroke in people with atrial fibrillation (AF), a common type of irregular heartbeat, who recently had a bleed in their brain, called an intracerebral haemorrhage (ICH).
At the heart of the EU-funded project was a clinical trial gathering evidence around recommended medication to prevent further stroke in ICH patients with AF. Alongside the main trial were sub-studies exploring other factors such as individual risk prediction, genetics, blood-based biomarkers, drug adherence and exposure, and psychological and cognitive factors.
The trial recruited 319 patients across 63 hospitals in 6 countries. Results from the PRESTIGE-AF clinical trial are expected in early 2025.
PRESTIGE-AF received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 754517.